Skip to content

Axsome Therapeutics AXSM Amortization of capitalized software and acquired intangible assets

Amortization of capitalized software and acquired intangible assets at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Abbott logo
AbbottABT

Other financials

Income statement

See full
Revenue$191.2M+57.4%
Gross profit$176.5M+58.0%
Operating income-$63.4M-11.2%
Net income-$64.5M-8.6%
EPS (diluted)-$1.26-3.3%

Balance sheet

See full
Cash & equivalents$305.1M+1.4%
Total debt$219.9M+4.1%
Total equity$54.6M+2.6%
Total assets$713.6M+19.6%

Cash flow

See full
Operating cash flow-$20.7M+52.3%
CapEx$121.0K-64.2%
Free cash flow-$20.8M+52.4%

Valuation

See full
Market cap$12.89B+52.0%
Enterprise value$12.81B+52.9%
P/S18.2×-1.4×

Profitability

See full
Gross margin92.6%+1.1pp
Operating margin-24.4%-9.3pp
Net margin-26.6%-9.8pp
FCF margin-10.2%-3.9pp

Returns & leverage

See full
Return on equity-349.4%+109pp
Debt / equity+0.1×
Current ratio1.4×-0.6×

Where this comes from

Reported directly by Axsome Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axsome Therapeutics's amortization of capitalized software and acquired intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Axsome Therapeutics's amortization of capitalized software and acquired intangible assets?
Axsome Therapeutics (AXSM) reported amortization of capitalized software and acquired intangible assets of $1.57M in Q1 2026.
How has Axsome Therapeutics's amortization of capitalized software and acquired intangible assets changed year-over-year?
Axsome Therapeutics's amortization of capitalized software and acquired intangible assets decreased by 0.0% year-over-year, from $1.57M to $1.57M.
What is the long-term trend for Axsome Therapeutics's amortization of capitalized software and acquired intangible assets?
Over 3 years (2022 to 2025), Axsome Therapeutics's amortization of capitalized software and acquired intangible assets has grown at a 15.5% compound annual growth rate (CAGR), from $4.14M to $6.38M.